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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects and safety of chlamydia screening in pregnant and non-pregnant women and in men, compared with standard
care, on chlamydia transmission and on complications of infection.
B A C K G R O U N D
Description of the condition
Genital infections caused by Chlamydia trachomatis serovars D-
K are the most prevalent bacterial sexually transmitted infection
worldwide, with an estimated 106 million people being infected
in 2008 (WHO 2012). In this protocol we use the term ’chlamy-
dia’ to describe these infections. Chlamydia is the most com-
mon notifiable infection in the USA, with 1,307,893 infections
reported in 2011 compared with 309,341 cases of gonorrhoea,
which is the second most common notifiable condition (CDC
2010). Chlamydia is also the most commonly reported infection
in Europe (ECDC 2011), Australia (DoHA 2011) and Canada
(PHAC 2006). Chlamydia is most common in young sexually ac-
tive adults. The prevalence of chlamydia has been estimated to be
about 3% to 5% in nationally representative samples of sexually
experienced women and men aged 25 years and under in high-
income countries (Fenton 2001; Klavs 2004; Miller 2004; Goulet
2010; Bozicevic 2011).
C. trachomatis is a gram negative obligate intracellular bacterium,
which infects columnar epithelium in the lower genital tract in
women and men and can also infect the rectum, pharynx, con-
junctiva (Stamm 2008) and placenta (Rours 2011). Chlamydia
infection causes complications, most commonly resulting from
spread from the lower to the upper genital tract. Upper gen-
ital tract infection occurs in both sexes but is more common
and has more severe consequences in women (Stamm 2008). In
women, chlamydia ascends to the upper genital tract in approx-
imately 10% of cases to cause symptomatic pelvic inflamma-
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tory disease (PID) (Oakeshott 2010; Herzog 2012). The result-
ing tubal damage can then cause ectopic pregnancy, tubal infer-
tility and chronic pelvic pain (Paavonen 2008). Although about
45% of tubal infertility might be attributable to chlamydia infec-
tion (Price 2012), the probability of tubal infertility in women
who have had chlamydia is estimated to be only 1% to 4% (Land
2010; Kavanagh 2013). Chlamydia infection in pregnancy is as-
sociated with preterm labour (Rours 2011) and can infect the
neonate, causing ophthalmia neonatorum and atypical pneumo-
nia (Kohlhoff 2008). C. trachomatis can cause epididymo-orchitis
in men, but its role in prostatitis and male infertility is not well-
established (Stamm 2008). Chlamydia can also cause Reiter’s syn-
drome in men (Stamm 2008) and is a co-factor for HIV infection,
increasing both susceptibility and infectiousness (Fleming 1999).
Uncomplicated genital chlamydia infections are usually asymp-
tomatic in both women and men (Stamm 2008) and untreated
infections last more than a year on average (Althaus 2010). C. tra-
chomatis can be treated with tetracyclines (usually doxycycline) or
macrolide (usually azithromycin) antibiotics with short-term mi-
crobiological cure rates of 90% to 95% (Manhart 2013). Immu-
nity after chlamydia infection is incomplete and repeated chlamy-
dia infection is common (Batteiger 2010a). In studies of women
enrolled from primary care and sexual health clinics and followed
up prospectively, about 25% of women treated for chlamydia had
the infection detected again in the year after treatment (Scott
LaMontagne 2007;Walker 2012). There are several reasons for re-
peated detection of chlamydia. In one prospective study amongst
young women in the USA, Batteiger et al. combined information
about sexual behaviour and genotype from 183 women with more
than one episode of chlamydia infection to estimate that about
66% of infections were probably acquired from a new partner,
17% were re-infections from untreated or inadequately-treated
sexual partners, 14% were probable antibiotic treatment failures
and 3% persisted without treatment (Batteiger 2010b). There is
some evidence to suggest that immunity after natural clearance
of chlamydia infection lasts longer than immunity after antibiotic
treatment (Geisler 2013).
Description of the intervention
Screening of sexually active young adults is the only way to detect
most chlamydia infections because of the lack of symptoms or
clinical signs in most infected people. Screening is a process of
identifying apparently healthy people whomay be at increased risk
of a disease or condition. They can then be offered information,
further tests and appropriate treatment to reduce their risk and/or
any complications arising from the disease or condition (UKNSC
2013).
There are two goals of screening for genital chlamydia infection:
first, to control the transmission of chlamydia and reduce the
prevalence of infection in the population; and second to reduce
the risk of complications, especially reproductive tract complica-
tions in women (Meyers 2007; NCSP 2010). Screening is a pro-
gramme, not a test (Raffle 2007). This means that screening in-
cludes the whole system of events needed to reach the endpoint of
reducing the risk of disease or complications. For chlamydia infec-
tion, screening includes offering a test to diagnose C. trachomatis,
treating people with a positive test, partner notification to identify
and treat sexual partners and repeated screening to detect and treat
newly acquired infection or re-infection.
The target group for chlamydia screening is usually defined by
age and sex. For example, chlamydia screening in the USA is rec-
ommended for women aged 25 years and under (CDC 2010), in
Australia for women under 25 years (RACGP 2007), and in the
UK for women and men aged 25 years and under (NCSP 2010).
Whilst behavioural and demographic factors can be used to iden-
tify groups at higher risk of chlamydia infection (Stergachis 1993;
Gotz 2005), risk factors differ between populations and selective
criteria can be difficult to apply in practice.
Chlamydia screening can be offered systematically, using a pop-
ulation register to invite people in the target age group (van den
Broek 2012). More commonly, screening is recommended as an
opportunistic activity to be offered to eligible young adults attend-
ing healthcare services (RACGP 2007; CDC 2010; NCSP 2010).
Repeated screening is recommended in some countries, given the
frequency of repeated chlamydia and the fact that young adults
may change sexual partners over time. In England, the National
Chlamydia Screening Programme recommends a screening test
every year or after a change of sexual partner (NCSP 2010). Vis-
its for cervical cancer screening in young women can be used as
an opportunity to offer chlamydia screening in some countries,
where the target age groups and screening frequency overlap. In
the UK, however, cervical cancer screening is only recommended
for women over 25 years.
How the intervention might work
The way in which chlamydia screening might work depends on
the goal of screening. To reduce chlamydia prevalence and inci-
dence, the coverage of screening has to be high enough to iden-
tify and treat prevalent cases of chlamydia and to interrupt chains
of chlamydia transmission in the population. Screening also has
to be frequent enough to prevent repeated infections because of
the limited immunity after treatment. Mathematical models show
that chlamydia screening reduces prevalence over time; in several
models, screening of 30% or more of the target population each
year is needed to reduce chlamydia prevalence markedly (Regan
2008; Althaus 2012).
There are two ways in which screening for chlamydia might
work to prevent reproductive tract complications (Peterman 2009;
Herzog 2013). First, direct prevention of PID occurs if screening
detects and treats an endocervical chlamydia infection in an in-
dividual woman before the infection ascends in the genital tract
to cause PID and subsequent tubal damage. The effectiveness of
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screening depends on the timing of progression from lower to up-
per genital tract infection. If PIDoccurs immediately, or shortly af-
ter the initial lower genital tract infection, there is no opportunity
for screening to work (Smith 2007; Herzog 2012). Randomised
controlled trials (RCTs) have shown that the incidence of clinically
diagnosed PID is lower in women actively invited for chlamydia
screening compared to those receiving usual care (Scholes 1996;
Ostergaard 2000; Oakeshott 2010; Andersen 2011). Women in-
fected with chlamydia who are enrolled into trials have persisting
prevalent infections with an unknown date of infection. The trial
findings and supportive evidence from mathematical modelling
studies suggest, therefore, that PID development can occur during
the course of infection (Herzog 2012). Second, prevention of the
transmission of chlamydia through screening and treatment has
an indirect effect on the risk of PID because the risk of becoming
infected with chlamydia in the first place falls.
Preventionof PID should lead to a reduction in the incidence of ec-
topic pregnancy and tubal infertility if tubal scarring is prevented.
It is, however, very difficult to measure the impact of chlamydia
screening on these outcomes because women in the age groups at
highest risk of chlamydia infection are usually using contraception.
In one RCT, the incidence of ectopic pregnancy and infertility af-
ter 11 years of follow-up were similar in women who had received
a single invitation to be screened for chlamydia and women who
received usual care (Andersen 2002).
There are also potential harms of chlamydia screening. First, a
woman who has been treated for chlamydia becomes susceptible
and is at risk of repeated infection and PID. It has been suggested
that the risk of PID is higher with subsequent chlamydia infections
(Hillis 1997), possibly because repeated exposure to C. trachoma-
tis antigens can cause immune mediated tubal damage (Brunham
2005). Second, being diagnosed with a sexually transmitted in-
fection can have a negative emotional and psychological impact
on the infected person (Mills 2006; Gottlieb 2011). In one study
in the USA, sexual partnerships broke down for 33% of women
with a positive chlamydia test result compared with 11% of those
receiving a negative result (Gottlieb 2011). Third, the experience
of screening can cause anxiety. In a study in the UK, however,
chlamydia screening did not increase anxiety or depression and
did not reduce self-esteem (Campbell 2006).
Why it is important to do this review
Screening for chlamydia infection is widely recommended (
RACGP 2007; CDC 2010; NCSP 2010; Low 2012) and widely
practised. Rates of chlamydia testing amongst young adults are
high (4000 to 9000 per 100,000 population) in several high-in-
come countries (Bender 2011). There is a strong rationale for early
detection and treatment of chlamydia infection in asymptomatic
young adults to reduce both transmission and complications (Low
2013). Widespread screening for asymptomatic chlamydia infec-
tion has the potential to cause harm, however, especially if the
rate of repeated infection after treatment outweighs the benefits
of detecting and treating asymptomatic infections, or if receiving
a diagnosis of chlamydia results in the breakdown of a relation-
ship (O’Farrell 2013). There are few data about long-term trends
in chlamydia prevalence in countries that recommend chlamydia
screening. In the USA, repeated cross-sectional studies show that
chlamydia prevalence fell between 1999 and 2008 in 14 to 39 year
olds as a whole, but not in 15 to 25 year old women, who are the
target population for screening (Datta 2012).
There is a systematic review of the effectiveness of chlamydia
screening interventions in studies published up to 2007 (Low
2009). There are new RCTs showing that a one-off screening in-
vitation could reduce the incidence of PID one year later (Scholes
1996; Ostergaard 2000). Also, we know that there are new com-
pleted trials with PID (Oakeshott 2010; Andersen 2011) and
transmission (van den Broek 2012) as endpoints, and at least one
ongoing trial (Hocking 2012). It is therefore important to develop
a Cochrane review about this issue.
O B J E C T I V E S
To assess the effects and safety of chlamydia screening in pregnant
and non-pregnant women and in men, compared with standard
care, on chlamydia transmission and on complications of infec-
tion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, non-randomised controlled trials.
If there are no RCTs addressing a primary outcome of chlamydia
screening, we will include non-randomised studies. Chlamydia
screening is a complex population-based intervention, one aim of
which is to reduce chlamydia prevalence in a population. This is an
outcome that is unlikely to be studied in RCTs (Cochrane 2011).
Cluster-randomisation is technically possible, but our previous
systematic review did not find any RCTs that examined the effect
of chlamydia screening on chlamydia transmission (Low 2009).
With cluster allocation, trials will be eligible if the groups receive
the intervention during different time periods, as long as baseline
and outcome data were collected prospectively using the same
criteria throughout the trial period. The risk of bias in methods of
allocation will be assessed and results from randomised and non-
randomised study designs will be analysed separately.
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We will exclude cohort studies, case-control studies, and inter-
rupted time-series studies.
Types of participants
Women and men (heterosexual or men who have sex with men)
aged over 13 years in any setting. The minimum age group is
arbitrary but aims to identify only studies of sexually transmitted
chlamydia infections.
Types of interventions
Intervention: Screening for sexually transmitted genital chlamydia
infection, defined as the offer of a test to apparently healthy people
to identify those at increased risk of chlamydia infection. This
definition is adapted from the UKNational Screening Committee
(UKNSC 2013). We will include any test used to diagnose genital
chlamydia infection.
Comparison: Inactive control (no offer of screening or standard
care).
Types of outcome measures
Eligible trials must include at least one of the pre-specified primary
outcomes. The primary outcomes will be measures of morbidity
that a chlamydia screening programme aims to prevent. One crite-
rion for assessing the effectiveness of a screening programme is that
‘There should be evidence from high quality Randomised Con-
trolled Trials that the screening programme is effective in reducing
mortality or morbidity’ (http://www.screening.nhs.uk/criteria).
Primary outcomes
We include one primary outcome for each goal of chlamydia
screening:
• Outcome for C. trachomatis transmission: Prevalence of
chlamydia infection in women and men at least 12 months after
the start of the screening intervention. Prevalence is estimated as
the number of positive chlamydia tests divided by the number of
people tested.
• Outcomes for reproductive tract morbidity: Incidence of
upper genital tract infection in women and men in the 12
months after the offer of screening. Pelvic inflammatory disease
(women) or epididymitis (men) are clinical diagnoses, made
using clinical criteria defined in advance by the authors.
Examples include criteria published by the US Centers for
Disease Control and Prevention (CDC 2010), or Hager and
Eschenbach (Hager 1983).
• Outcome for chlamydia infection in pregnancy: Incidence
of preterm delivery. Preterm delivery is defined as delivery at a
gestational age of less than 37 weeks, with subgroups of
gestational ages less than 32 weeks and less than 35 weeks (Rours
2011).
Secondary outcomes
Outcomes measured in all participants:
• Proportion of participants receiving the intervention,
defined as the number tested for chlamydia divided by the
number eligible and invited to take part.
• Harms of screening, including psychological distress,
partner violence, relationship breakdown, using definitions
described by the authors.
Outcomes measured in women who were not pregnant during the
trial or in men:
• Prevalence of chronic female pelvic pain, defined as patient-
reported pain in the lower abdomen or pelvis lasting at least six
months (Paavonen 2008).
• Prevalence of female or male infertility, defined using a
clinical definition of lack of pregnancy despite unprotected
intercourse for 12 months or more (Paavonen 2008).
Outcomes measured in women who were pregnant during the
trial, or in their infant:
• Incidence of C. trachomatis neonatal conjunctivitis, defined
as C. trachomatis isolated from the conjunctiva by culture or
detected by nucleic acid amplification test (Kohlhoff 2008).
• Incidence of C. trachomatis neonatal pneumonitis, defined
as signs of lower respiratory tract infection presenting between 4
and 12 weeks with C. trachomatis isolated from the nasopharynx
by culture or detected by nucleic acid amplification test
(Kohlhoff 2008).
The following outcome will not be included: uptake of chlamydia
screening. Screening uptake is an intermediate outcome. The re-
lationship between uptake of screening and the primary outcomes
has not been quantified so, for a given level of screening uptake,
it is not possible to predict the expected reduction in chlamydia
prevalence or incidence of pelvic inflammatory disease.
Search methods for identification of studies
We will attempt to identify trials meeting the inclusion criteria
irrespective of their language, publication date and publication
status (published, unpublished, in press, and in progress). We will
use both electronic searching in bibliographic databases and hand-
searching, as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a).
The results of all searches will be downloaded and managed using
Endnote bibliographic software. Duplicate records of the same
study will be deleted.
Electronic searches
We will contact the Trials Search Coordinator (TSC) of the Sex-
ually Transmitted Infections Cochrane Review Group in order to
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implement a comprehensive search strategy which seeks to cap-
ture as many relevant trials as possible in electronic databases.
For this purpose, we will use a combination of controlled vo-
cabulary (MeSH, Emtree, DeCS, including exploded terms) and
free-text terms (considering spelling variants, plurals, synonyms,
acronyms and abbreviations) for “genitalChlamydia infection” and
“screening”, with field labels, truncation, proximity operators and
boolean operators. The sensitivity of the search strategies will be
improved by including keywords from relevant trials detected by
earlier searches. We present the search strategies in Appendix 1
(Electronic search strategies).
Specifically, we will search in the following electronic databases:
• MEDLINE, Ovid platform: inception to present.
• MEDLINE In-Process & Other Non-Indexed Citations,
Ovid platform: inception to present.
• MEDLINE Daily Update, Ovid platform: inception to
present.
• EMBASE.com: inception to present.
• The Cochrane Central Register of Controlled Trials
(CENTRAL), Ovid platform: inception to present.
• LILACS, iAHx interface: inception to present.
• CINAHL: inception to present.
• Database of Abstracts of Reviews of Effects (DARE):
inception to present.
• PsycINFO: inception to present.
We will searchingMEDLINE using the Cochrane highly sensitive
search strategy for identifyingRCTs: sensitivity and precisionmax-
imizing version (2008 revision), Ovid format (Higgins 2011a).
The LILACS search strategy will be combined with the RCT filter
of the iAHx interface.
These searches will be updatedwithin 6months before publication
of the review.
Searching other resources
We will attempt to identify additional relevant trials using the
following methods:
1. Searching in the Sexually Transmitted Infections (STI)
Cochrane Review Group’s Specialised Register, which includes
RCTs and controlled clinical trials, from 1944 to 2012, located
through:
• Electronic searching in MEDLINE, EMBASE and
CENTRAL.
• Handsearching in those journals not indexed in MEDLINE
or EMBASE (according to the journals’ master list of the STI
Cochrane Review Group): Anatolian Journal of Obstetrics &
Gynecology, Current Medical Literature Gynecology &
Obstetrics, Current Obstetrics and Gynecology Reports, ISRN
Obstetrics and Gynecology, Journal of South Asian Federation of
Obstetrics & Gynecology, Obstetrics and Gynecology
International, Obstetrics Gynaecology and Reproductive
Medicine, Sexual Science: the newsletter of the Society for the
Scientific Study of Sexuality and Sexualities.
2. Searching trials registers:
• WHO International Clinical Trials Registry Platform
(ICTRP) portal (http://apps.who.int/trialsearch/): inception to
present.
• ClinicalTrials.gov (http://clinicaltrials.gov/): inception to
present.
3. Searching Web of Science®: inception to present.
4. Searching for grey literature in System for Information on Grey
Literature in Europe “OpenGrey” (http://www.opengrey.eu/): in-
ception to present.
5. Contacting authors of all RCTs identified by other methods. A
comprehensive list of trials included in the review along with the
criteria for considering studies will be sent to the first author of
each included study, asking for any additional studies published
or unpublished that might be relevant.
6. Handsearching conference proceeding abstracts from the fol-
lowing events:
• The International Society for Sexually Transmitted Diseases
Research - ISSTDR (http://www.isstdr.org/): 2007, 2009 and
2011.
• The British Association for Sexual Health and HIV -
BASHH (http://www.bashh.org/): 2004, 2006, 2007 and 2009.
• International Congress on Infectious Diseases - ICID (
http://www.isid.org/): 2010 and 2012.
• The International Union against Sexually Transmitted
Infections - IUSTI (http://www.iusti.org/): 2011 and 2012.
• International Society for Infectious Diseases - ISID (http://
www.isid.org/): 2011.
• International Meeting on Emerging Diseases and
Surveillance - IMED (http://www.isid.org/): 2007, 2009 and
2011.
• Interscience Conference on Antimicrobial Agents and
Chemotherapy - ICAAC (http://www.icaac.org/): 2011 and
2012.
• The International Federation of Gynecology and Obstetrics
- FIGO (http://www.figo2012.org/home/): 2012.
7. Handsearching previous systematic reviews and other relevant
publications on the same topic.
8. Handsearching reference lists of all relevant RCTs identified by
other methods.
Data collection and analysis
Selection of studies
Two review authors (NL, SR) will review titles and abstracts of
articles identified by the search strategy independently, using a pi-
lot-tested form to document potential eligibility. Disagreements
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will be discussed. We will obtain the full text manuscripts of all
articles agreed as being potentially eligible by both review authors,
articles about which the authors still disagree after discussion, and
articles with no abstract if there is insufficient information avail-
able from the title or publication type to make a decision. If the
disagreement cannot be resolved by discussion, the full text of the
article will be obtained.
The abstracts of articles identified through searching other re-
sources will be assessed using the same criteria as for studies iden-
tified through electronic database searches.
Two independent review authors will examine full text articles
using a pilot-tested form to assess eligibility for inclusion. Studies
identified by both authors as being eligible for inclusion will be
included in the review. Where there are discrepancies, the authors
will discuss the article and reach a consensus decision. If there is
no agreement, a third independent author will adjudicate to make
a final decision about eligibility.
We will use a flow chart to document the numbers of articles
assessed and included or excluded at each stage, with a summary
of reasons for exclusion. The flow chart will show the total number
of studies included in the review and the total number of articles
pertaining to these studies.Wewill record briefly the characteristics
of studies excluded from the review if readers might expect them
to have been included.
Data extraction and management
Wewill develop and pilot standardised forms to extract data about:
• Study location and setting
• Trial design and power calculation
• Ethical approval
• Inclusion and exclusion criteria
• Baseline characteristics of trial participants including sex,
age, sexual orientation, pregnancy status for women, diagnostic
test used to detect C. trachomatis
• Types of intervention: opportunistic or systematic invitation
for screening; number of screening rounds, screening interval
• Types of comparison group: usual care, alternative screening
method
• Types of outcome: primary, secondary
• Reporting of methodological characteristics (see next
section, Assessment of risk of bias in included studies for details)
We will extract the following numerical data:
• Number of people assessed for eligibility
• Numbers randomised to intervention and comparison
groups
• Numbers receiving screening in intervention and
comparison groups (at each screening round if multiple rounds)
• Numbers included in analyses in intervention and
comparison groups
• Numbers with outcomes in intervention and comparison
groups
One author (SR) will extract data about study characteristics and
a second will check these details. They will resolve discrepancies
by discussion or a third independent author will adjudicate.
Two appropriately authors (from all co-authors) will extract and
enter numerical data independently from each included study into
Epidata using a structured form. If there are multiple publications
relating to the same study, data items can be extracted from differ-
ent publications. If there are discrepancies between publications
about a data item, we will use the data presented in the main
trial publication (the publication that includes the results for the
primary outcome) or the first chronological publication reporting
that data item.
Articles in languages other than English will either be translated
first and then duplicate data extraction conducted as above or,
if there are two review authors who understand the language of
publication, they will extract the data directly.
The two files will be compared using the validation function avail-
able in Epidata. Discrepancies in data extraction or data entry will
be resolved by consensus. If there is no agreement a third indepen-
dent author will adjudicate to make a final decision. The agreed
data will be entered into Review Manager 5 (RevMan) software.
If there are insufficient details given to allow the extraction of nu-
merical data, the study will be included and the results described.
Assessment of risk of bias in included studies
Wewill assess themethods reported to have been used in the design
and execution of all included trials. The assessment will determine
whether there is a risk of bias that would over- or underestimate
the effect of the intervention on one or more outcomes (Higgins
2011a). This assessment relies on reports of methods described by
trial authors in publications and, where available, trial protocols.
For any trial, the findings of the assessment can only say whether
there is a risk of biased results, and cannot determine whether the
results themselves are or are not biased.
For both randomised and non-randomised trials we will assess the
risk of five specific sources of bias: selection bias, performance bias,
detection bias, attrition bias and reporting bias; and will record
any other biases related to a particular trial.
For RCTs we will use the Cochrane Collaboration’s ‘Risk of bias’
tool and criteria in the Cochrane Handbook (Table 8.5.d) to assess
these in the relevant domains of the reported methods and results
(Cochrane 2011).
Selection bias is only the domain for which there are important
differences in assessing the risk of bias in randomised and non-
randomised controlled trials. For non-randomised controlled trials
wewill use theUKNational Insitute ofHealth andCare Excellence
(NICE) ’methodology checklist’ for cohort studies to assess the risk
of selection bias (NICE 2012). The NICE methodology checklist
format follows that of the Cochrance Collaboration tool, with
criteria to assess bias in each domain and a choice of low, high or
unclear risk of bias. We will use the Cochrane risk of bias tool to
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assess non-randomised controlled trials for risks of performance,
detection, attrition and reporting biases.
Assessors will record whether there is a low, high or unclear risk of
bias in each domain of each included trial and give a justification
for their decision. For each included trial there will be two inde-
pendent assessors, including at least one expert in trial method-
ology (NL) and at least one expert in chlamydia screening (HG).
They will resolve discrepancies by discussion. If they cannot agree,
a third author will adjudicate.
The domains and their source are summarised here:
(1a) Random sequence generation (possible selection bias,
Cochrane ‘Risk of bias’ tool)
Selection bias could occur if allocation to intervention or control
groups can be predicted in advance and if participants or clusters
of participants are enrolled selectively. The method used to gen-
erate the allocation sequence should be unpredictable and should
balance prognostic factors, on average, across intervention and
comparison groups. We will assess the method as being at:
• low risk of bias (adequate description of a truly random
process, e.g. random number tables, computer generated random
numbers);
• high risk of bias (explicit description of an allocation
process that is not truly random, e.g. odd or even dates of birth
of individuals, clusters of participants selected for
implementation of the intervention with subsequent enrolment
of comparison groups);
• unclear risk of bias (description that does not include
enough information to decide whether sequence generation was
truly random or not).
(1b) Allocation concealment (possible selection bias,
Cochrane ‘Risk of bias’ tool)
Selection bias can occur if participants or clusters of participants
are selectively enrolled and allocated to a particular group and if
their characteristics are associated with the outcome. If the se-
quence has been randomly generated, selective enrolment can oc-
cur if the next assignment is known before allocation. Conceal-
ment of the allocation sequence up to the point of assignment
prevents selective assignment to a particular intervention group.
We will assess the methods of allocation concealment as:
• low risk of bias (adequate description of a process that
prevented foreknowledge of allocation up to the point at which
assignment was recorded, e.g. telephone or central
randomisation);
• high risk of bias (description of a process that meant that
those assigning participants or clusters of participants knew or
could predict the allocation in advance);
• unclear risk of bias (insufficient details to be able to decide
whether the allocation was concealed or not).
(1c) Systematic differences between comparison groups (pos-
sible selection bias, NICE ’methodology checklist’)
In a non-randomised trial, selection bias can occur because of the
lack of a random allocation sequence and concealed allocation. If
the person assigning individuals or clusters to a particular group
knows about the distribution of factors associated with the out-
come, they might introduce selection bias. We will assess the risk
of selection bias as:
• low risk of bias ((a) the reason for participant allocation to
treatment groups is not expected to affect the outcomes of the
study, (b) there were attempts made within the design or analysis
to balance the comparison groups for potential confounders and
(c) the groups were comparable at baseline for all known major
confounders and prognostic factors);
• high risk of bias (any of (a) to (c) above not fulfilled);
• unclear risk of bias (insufficient details to be able to decide
whether there was a risk of systematic differences between
comparison groups).
(2) Blinding of participants and personnel (possible perfor-
mance bias)
Screening is an intervention that involves systematic differences
in the delivery of a health service. Personnel who offer chlamydia
screening tests might offer other sexual health information, advice
or interventions, such as condoms, that could affect participants’
risk of chlamydia infection or another outcome. Such information
and interventions could also be considered a part of the screening
programme, however. Trial participants or clusters of participants
in an inactive ‘usual care’ control group might also be considered
blinded if they do not know that they are part of a trial. For each
included trial, we will describe the intervention. We will consider
studies as being at low risk of bias if participants were blinded
or if the lack of blinding would be unlikely to affect results for a
particular outcome.
(3) Blinding of outcome assessment (possible detection bias)
For chlamydia screening interventions, adequate descriptions of
blinding of those assessing the outcomes are important. We will
group outcomes that are objectively assessed, e.g. chlamydia test
results obtained from automated diagnostic systems, and those
that are subjective, e.g. clinical diagnosis of pelvic inflammatory
disease.
The incidence of clinically diagnosed pelvic inflammatory disease
is a primary outcome of chlamydia screening interventions. The
main symptom is lower abdominal pain, which is common and
non-specific. Knowledge of group assignment could influence the
interpretation of symptoms by both trial participants and person-
nel delivering the intervention in unpredictable ways. For exam-
ple, healthcare providers who know whether a woman has been
screened for chlamydia might be more likely to assign a diagno-
sis of pelvic inflammatory disease to a woman who presents with
abdominal pain because of increased awareness of the complica-
tions of chlamydia infection. On the other hand, they might be
reassured if the test was negative or if treatment had been given
and then interpret abdominal pain with or without accompanying
signs as resulting from another cause. Women who have accepted
or declined screening might also modify their assessment of symp-
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toms or their health-seeking behaviour. For subjective outcomes,
we will assess methods as follows:
• low risk of bias (adequate description of assessment that
reduced the risk of bias, e.g. uniform assessment of all trials
participants by an independent assessor blinded to allocation, or
assessment of diagnoses by an independent assessment panel
blinded to allocation);
• high risk of bias (assessment of outcomes by personnel who
knew the group assignment);
• unclear risk of bias (insufficient information to determine
whether outcome assessment was blinded or not).
(4) Incomplete outcome data (possible attrition bias due to the
amount, nature and handling of incomplete outcome data)
For each outcome or class of outcomes we will describe the com-
pleteness of data and exclusions from analysis in each included
trial. We will state whether analyses were conducted and reported
according to intention-to-treat or not. Where reported we will
state numbers included in the analysis as a proportion of the totals
randomised to intervention and comparison groups, reasons for
attrition or exclusion, and whether missing data were balanced
across groups or were related to outcomes. Where sufficient infor-
mation is reported, or can be supplied by the trial authors, we will
re-include missing data in our analyses. We will use a cut-off of
20% to assign trials with missing outcome data as being at low or
high risk of bias. In addition, we will assess methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias (insufficient information about missing
data or exclusions from analysis).
(5) Selective outcome reporting (possible reporting bias)
Where available, we will assess the trial protocol and trial registra-
tion documents as well as articles or publications resulting from a
trial. We will describe the documents available for each included
study and assess the methods as follows:
• low risk of bias (adequate description that all pre-specified
outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (explicit evidence that not all pre-specified
outcomes have been reported, that one or more reported primary
outcomes were not pre-specified, that outcomes of interest are
reported incompletely and cannot be used in the review, or that
there are no results for a key outcome that would have been
expected to have been reported);
• unclear risk of bias (insufficient information to decide
whether selective reporting bias is likely or not).
(6) Other biases
For each included trial we will describe other potential sources
of bias. For example, the effects of chlamydia screening can be
assessed in cluster-randomised trials. We will describe design-spe-
cific risks of bias in domains such as recruitment, baseline imbal-
ances and appropriate statistical analysis. We will report whether
these are likely to result in a low, high or unclear risk of bias.
(7) Overall risk of bias
For each primary outcome we will assess the overall level of evi-
dence provided by the included trials using theGRADE approach,
as incorporated in Review Manager 5. We will produce a ’Sum-
mary of findings’ table (Higgins 2011b). The level of evidence is
summarised as high, moderate, low or very low. We will give jus-
tifications for changing the level of evidence depending on find-
ings about: study limitations; consistency of results; directness of
evidence; imprecision; publication bias.
Measures of treatment effect
All pre-specified primary and secondary outcomes are dichoto-
mous.
The treatment effect or harmful effect for each, comparing the
outcome in those receiving the screening intervention with the
control group, can be expressed as a relative risk (RR) with 95%
confidence intervals (CI). An advantage of the RR is that it can be
interpreted easily for both high and low event rates. We will also
calculate the risk difference (RD, 95% CI), the actual difference
in the event rate between intervention and control groups. We will
use the risk difference to calculate the number needed to treat to
benefit (NNTB) or number needed to treat to harm (NNTH).
For the primary outcome of chlamydia prevalence, we will re-
port the overall effect estimate at the level of the cluster, and state
whether the analysis has taken into account the correlation be-
tween individuals within a cluster. We will not combine estimates
from individually and cluster-randomised trials.
Unit of analysis issues
If a trial involves more than one intervention group, we will de-
scribe all of the groups in the ‘Characteristics of included stud-
ies’ table. We will analyse only those relevant to the pre-specified
primary and secondary outcomes; however. If necessary, we will
combine results of multiple intervention or comparison groups so
that only single pair wise comparisons are made.
Cluster-randomised trials of chlamydia screening interventions
might measure the effect of the intervention in a geographic area
or a school community. In trials of chlamydia screening, the inter-
vention affects not only individuals who are screened and treated
(direct effect), but their sexual partners and members of the same
sexual network (indirect effect). The indirect effect of screening
can reduce the level of repeated exposure to infection of individ-
uals within a cluster.
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Dealing with missing data
We will report the percentage of observations with missing data in
each included trial. We will use sensitivity analysis to explore the
effect of including or excluding trials with high levels of missing
data.
For each outcome we will attempt to analyse data according to
the intention-to-treat principle, with all participants included in
the group to which they were randomised and exclusion only of
participants with missing outcome data.
Assessment of heterogeneity
We will report statistical heterogeneity in results between studies
using I2, tau2 and Chi2 statistics obtained from analyses in Review
Manager 5. We will use the I2 statistic to quantify the percentage
of variability between the results that is due to heterogeneity rather
than sampling error (Higgins 2002). We will take into account
the fact that I2 values are affected by the number of studies, the
magnitude and direction of effects in individual trials, and the
strength of evidence of heterogeneity. In general, we will consider
I2 values less than 40% as showing little evidence of statistical
heterogeneity.
Assessment of reporting biases
Wewill look for evidence of publication and other reporting biases
using funnel plots that plot the effect size against precision. If there
are more than 10 studies in a meta-analysis we will use statistical
tests of funnel plot asymmetry for continuous (Egger 1997) or
binary (Harbord 2005) endpoints.
Data synthesis
Wewill use narrative syntheses to describe the results of trialswhere
there are too few studies for meta-analysis or where we consider
that meta-analysis is not clinically meaningful. We will use forest
plots to display results of trials examining the same outcome.
Where appropriate, wewill combine data usingmeta-analysis con-
ducted in Review Manager 5. If there are trials that examine the
same intervention and are assumed to measure the same underly-
ing effect in similar populations, we will use a fixed-effect model.
If there is clinical heterogeneity or statistical evidence of substan-
tial statistical heterogeneity we will use a random-effects model
to estimate the average treatment effect across trials. The results
will be presented as the summary RR (95% CI) with I2 and tau2
estimates. For meta-analyses with at least three studies combined
using a random-effects model we will also calculate a prediction
interval to examine the range of effect estimates that might be ex-
pected in different settings or populations (Riley 2011). We will
not combine results from randomised and non-randomised trials
in the same meta-analysis, but will compare these in a sensitivity
analysis.
Subgroup analysis and investigation of heterogeneity
If there is evidence of substantial heterogeneity (I2 greater than
40%) for the primary outcome measures and if there are enough
trials, we will use subgroup analyses to explore it. We will explore
the following subgroups:
• Sex of the patient
• Level of sexual behaviour risk of the study population (high
risk, low risk)
• Uptake of the intervention (greater or less than 50%)
• Intensity of the intervention (single offer, multiple
screening rounds)
For fixed-effect models based on inverse variance meta-analysis,
we will use tests of interaction to examine differences between
groups. For random-effects models and fixed-effect models using
methods other than inverse variance we will inspect confidence
intervals for the subgroup estimates.
Sensitivity analysis
We will conduct sensitivity analyses to investigate the influence
of methodological aspects of the review that might influence the
results. We pre-specify the following sensitivity analyses:
1. The treatment effect for pelvic inflammatory disease
incidence in RCTs assessed as being at low versus high risk of
detection bias, i.e. blinded versus non-blinded assessment.
2. The treatment effect for each primary outcome in RCTs
assessed at being at low versus high risk of selection bias.
3. The treatment effect for chlamydia prevalence in RCTs
versus non-randomised studies.
4. The treatment effect for each primary outcome in
intention-to-treat versus per protocol study populations.
We will explore additional factors in sensitivity analysis if they
arise during analysis.
A C K N OW L E D G E M E N T S
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A P P E N D I C E S
Appendix 1. Electronic search strategies
MEDLINE and CENTRAL (Ovid platform)
1 exp Mass Screening/
2 screening$.tw.
3 tested.tw.
4 testing.tw.
5 or/1-4
6 exp Chlamydia/
7 chlam?di$.tw.
8 exp Chlamydia trachomatis/
9 exp Chlamydia Infections/
10 or/6-9
11 randomized controlled trial.pt.
12 controlled clinical trial.pt.
13 randomized.ab.
14 placebo.ab.
15 clinical trials as topic.sh.
16 randomly.ab.
17 trial.ti.
18 or/11-17
19 exp animals/ not humans.sh.
20 18 not 19
21 5 and 10 and 20
Note: the CENTRAL search strategy does not include the terms #11 to #20.
EMBASE.com
#1 ’mass screening’/exp
#2 screening*:ti,ab
#3 ’screening’/exp
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#4 tested:ti,ab
#5 testing:ti,ab
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 ’Chlamydia’/exp
#8 chlamydi*:ti,ab
#9 chlamidi*:ti,ab
#10 ’Chlamydia trachomatis’/exp
#11 ’chlamydiasis’/exp
#12 #7 OR #8 OR #9 OR #10 OR #11
#13 ’randomized controlled trial’/exp
#14 ’single blind procedure’/exp
#15 ’double blind procedure’/exp
#16 ’crossover procedure’/exp
#17 #13 OR #14 OR #15 OR #16
#18 random*:ab,ti
#19 placebo*:ab,ti
#20 allocat*:ab,ti
#21 crossover*:ab,ti
#22 ’cross over’:ab,ti
#23 trial:ti
#24 (doubl* NEXT/1 blind*):ab,ti
#25 #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
#26 #17 OR #25
#27 ’animal’/de
#28 ’animal experiment’/de
#29 ’nonhuman’/de
#30 #27 OR #28 OR #29
#31 ’human’/de
#32 #30 AND #31
#33 #30 NOT #32
#34 #26 NOT #33
#35 #6 AND #12 AND #34 AND [embase]/lim
LILACS (iAHx interface)
(mh:(tamizaje masivo)) OR (ti:(tamizaje)) OR (ab:(tamizaje)) OR (ti:(tamización)) OR (ab:(tamización)) OR (mh:(cribado)) OR
(ti:(cribado)) OR (ab:(cribado)) AND (mh:(chlamydia)) OR (ti:(chlamydi*)) OR (ab:(chlamydi*)) OR (ti:(chlamidi*)) OR (ab:
(chlamidi*)) OR (ti:(clamidia*)) OR (ab:(clamidia*)) OR (mh:(chlamydia trachomatis)) OR (mh:(infecciones por chlamydia)) AND
db:(“LILACS”) AND type_of_study:(“clinical_trials”)
Other resources
“Screening” and “Chlamydia” in title, abstract and keywords.
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